PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Analyze analyst forecasts for the company and compare them with competitors.
9.68M
The estimated revenue has increased from the previous period.
-1.93M
The estimated EBITDA has decreased from the previous period.
-1.38
The estimated EPS has increased from the previous period.
-41.62M
The estimated net income has decreased from the previous period.
-1.93M
The estimated EBIT has decreased from the previous period.
358.54M
The estimated SG&A expenses have increased from the previous period.
Analyze DCF forecasts for the company and compare them with competitors.
No Data
No DCF data available for this metric in the selected year.
-50.53%
Revenue growth rate has increased from the previous period.
No Data
No DCF data available for this metric in the selected year.
-20.00%
EBITDA margin has decreased from the previous period.
No Data
No DCF data available for this metric in the selected year.
-20.00%
EBIT margin has decreased from the previous period.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
100.00%
Cash percentage is unchanged from the previous period.
No Data
No DCF data available for this metric in the selected year.
40.00%
Receivables percentage has decreased from the previous period.
No Data
No DCF data available for this metric in the selected year.
40.00%
Inventory percentage has decreased from the previous period.
No Data
No DCF data available for this metric in the selected year.
100.00%
Payables percentage is unchanged from the previous period.
No Data
No DCF data available for this metric in the selected year.
-29.43%
CapEx percentage has increased from the previous period.
4.99%
WACC is unchanged from the previous period.
5.02%
Cost of equity is unchanged from the previous period.
4.08%
Cost of debt is unchanged from the previous period.
-0.23
Beta is unchanged from the previous period.
30.07M
Diluted shares outstanding is unchanged from the previous period.
1.57M
Total debt is unchanged from the previous period.
49.31M
Total equity is unchanged from the previous period.
50.89M
Total capital is unchanged from the previous period.
3.09%
Debt weighting is unchanged from the previous period.
96.91%
Equity weighting is unchanged from the previous period.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
2.00%
Long-term growth rate is unchanged from the previous period.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
-71.33M
Net debt is unchanged from the previous period.
71.33M
Equity value is unchanged from the previous period.
2.37
Equity value per share is unchanged from the previous period.
View analysts' price targets and recommendations, and compare them with competitors.
$11.07
Analysts expect the stock price to increase by 521.91%.
Buy
Positive consensus among analysts.